WEBVTT

00:00:02.200 --> 00:00:05.655
Thymosin alpha one opens our immune
defense and inflammation

00:00:05.680 --> 00:00:06.540
collection.

00:00:07.220 --> 00:00:09.980
Immune health depends on coordinated
responses.

00:00:10.840 --> 00:00:14.875
In nineteen seventy-seven, Allan Goldstein
and colleagues reported

00:00:14.900 --> 00:00:18.735
the isolation and sequence of this
twenty-eight-amino-acid peptide

00:00:18.760 --> 00:00:20.100
from calf thymus.

00:00:20.660 --> 00:00:24.640
Its synthetic counterpart has the same
amino acid sequence.

00:00:25.360 --> 00:00:28.700
Laboratory studies examine how it
influences dendritic cells,

00:00:29.120 --> 00:00:31.935
which help present information to T cells.

00:00:31.960 --> 00:00:36.135
This connects rapid innate defenses with
targeted adaptive

00:00:36.160 --> 00:00:36.980
responses.

00:00:38.020 --> 00:00:41.335
Changes in an immune marker are not
automatically clinical

00:00:41.360 --> 00:00:41.800
benefits.

00:00:42.540 --> 00:00:45.895
That distinction matters in sepsis, where
a dangerous response

00:00:45.920 --> 00:00:48.220
to infection can damage organs.

00:00:49.600 --> 00:00:53.155
The TESTS trial enrolled eleven hundred
six adults at

00:00:53.180 --> 00:00:54.720
twenty-two centers in China.

00:00:55.600 --> 00:01:00.435
Participants received thymosin alpha one
or placebo alongside

00:01:00.460 --> 00:01:01.635
standard care.

00:01:01.660 --> 00:01:05.335
Among the one thousand eighty-nine
participants analyzed,

00:01:05.360 --> 00:01:09.535
twenty-eight-day mortality was
twenty-three point four percent

00:01:09.560 --> 00:01:13.155
with the peptide and twenty-four point one
percent with

00:01:13.180 --> 00:01:13.680
placebo.

00:01:14.780 --> 00:01:18.220
The corrected report found no clear
mortality benefit.

00:01:19.020 --> 00:01:22.960
Its confidence interval included possible
benefit and harm.

00:01:23.620 --> 00:01:27.415
These findings describe a specific
treatment strategy in adults

00:01:27.440 --> 00:01:28.440
with sepsis.

00:01:29.080 --> 00:01:31.640
They do not settle every question about
thymosin alpha

00:01:32.500 --> 00:01:37.520
one or demonstrate an immune-boosting
benefit in healthy people.

00:01:38.480 --> 00:01:42.695
Similar reported safety outcomes do not
establish long-term

00:01:42.720 --> 00:01:43.400
safety.

00:01:43.980 --> 00:01:46.995
In the United States, it is not an
F-D-A-approved

00:01:47.020 --> 00:01:47.580
medicine.

00:01:48.460 --> 00:01:52.095
Connect immune biology to a defined
disease, a measured

00:01:52.120 --> 00:01:55.380
outcome, and the strength of the human
evidence.

00:01:56.180 --> 00:01:57.455
World Peptide Foundation.

00:01:57.480 --> 00:02:00.395
Peptides in 2.

00:02:00.420 --> 00:02:01.760
Every experience matters.